Edward A Neuwelt

Summary

Affiliation: Oregon Health and Science University
Country: USA

Publications

  1. pmc Platinum-induced ototoxicity in children: a consensus review on mechanisms, predisposition, and protection, including a new International Society of Pediatric Oncology Boston ototoxicity scale
    Penelope R Brock
    Great Ormond Street Hospital for Children National Health Service Trust, London, United Kingdom
    J Clin Oncol 30:2408-17. 2012
  2. ncbi request reprint Imaging of iron oxide nanoparticles by MR and light microscopy in patients with malignant brain tumours
    E A Neuwelt
    Department of Neurology, Oregon Health and Science University, Portland, OR, USA
    Neuropathol Appl Neurobiol 30:456-71. 2004
  3. ncbi request reprint Imaging changes and cognitive outcome in primary CNS lymphoma after enhanced chemotherapy delivery
    Edward A Neuwelt
    Department of Neurology, Oregon Health Sciences University, 3181 SW Sam Jackson Park Road, Portland, OR 97239, USA
    AJNR Am J Neuroradiol 26:258-65. 2005
  4. ncbi request reprint Bone marrow chemoprotection without compromise of chemotherapy efficacy in a rat brain tumor model
    Edward A Neuwelt
    Oregon Health Sciences University, Department of Neurology, Portland 97239, USA
    J Pharmacol Exp Ther 309:594-9. 2004
  5. ncbi request reprint Mechanisms of disease: the blood-brain barrier
    Edward A Neuwelt
    Department of Neurology, Oregon Health and Science University, Portland, Oregon 97201, USA
    Neurosurgery 54:131-40; discussion 141-2. 2004
  6. ncbi request reprint The potential of ferumoxytol nanoparticle magnetic resonance imaging, perfusion, and angiography in central nervous system malignancy: a pilot study
    Edward A Neuwelt
    Department of Neurology, Oregon Health and Science University, Portland, OR 97239, USA
    Neurosurgery 60:601-11; discussion 611-2. 2007
  7. ncbi request reprint Effect of antigenic heterogeneity on the efficacy of enhanced delivery of antibody-targeted chemotherapy in a human lung cancer intracerebral xenograft model in rats
    Leslie L Muldoon
    Department of Neurology, Oregon Health and Science University, and Veterans Administration Medical Center, Portland, Oregon 97201, USA
    Neurosurgery 53:1406-12; discussion 1412-3. 2003
  8. ncbi request reprint Therapeutic efficacy of aortic administration of N-acetylcysteine as a chemoprotectant against bone marrow toxicity after intracarotid administration of alkylators, with or without glutathione depletion in a rat model
    E A Neuwelt
    Department of Neurology, Oregon Health Sciences University, Portland, Oregon 97201, USA
    Cancer Res 61:7868-74. 2001
  9. pmc Dual contrast perfusion MRI in a single imaging session for assessment of pediatric brain tumors
    Eric M Thompson
    Department of Neurological Surgery, Oregon Health and Science University, 3303 SW Bond Avenue, CH8N, Portland, OR, 97239, USA
    J Neurooncol 109:105-14. 2012
  10. pmc Magnetic resonance imaging of intracranial tumors: intra-patient comparison of gadoteridol and ferumoxytol
    Edit Dosa
    Department of Neurology, Oregon Health and Science University, 3181 S W Sam Jackson Park Road, L603, Portland, OR 97239 3098, USA
    Neuro Oncol 13:251-60. 2011

Detail Information

Publications81

  1. pmc Platinum-induced ototoxicity in children: a consensus review on mechanisms, predisposition, and protection, including a new International Society of Pediatric Oncology Boston ototoxicity scale
    Penelope R Brock
    Great Ormond Street Hospital for Children National Health Service Trust, London, United Kingdom
    J Clin Oncol 30:2408-17. 2012
    ..Cisplatin causes hearing loss in at least 60% of pediatric patients. Reducing cisplatin and high-dose carboplatin ototoxicity without reducing efficacy is important...
  2. ncbi request reprint Imaging of iron oxide nanoparticles by MR and light microscopy in patients with malignant brain tumours
    E A Neuwelt
    Department of Neurology, Oregon Health and Science University, Portland, OR, USA
    Neuropathol Appl Neurobiol 30:456-71. 2004
    ..Our goal was to compare ferumoxtran imaging and histochemistry vs. gadolinium enhancement in malignant brain tumours on preoperative and postoperative MR...
  3. ncbi request reprint Imaging changes and cognitive outcome in primary CNS lymphoma after enhanced chemotherapy delivery
    Edward A Neuwelt
    Department of Neurology, Oregon Health Sciences University, 3181 SW Sam Jackson Park Road, Portland, OR 97239, USA
    AJNR Am J Neuroradiol 26:258-65. 2005
    ....
  4. ncbi request reprint Bone marrow chemoprotection without compromise of chemotherapy efficacy in a rat brain tumor model
    Edward A Neuwelt
    Oregon Health Sciences University, Department of Neurology, Portland 97239, USA
    J Pharmacol Exp Ther 309:594-9. 2004
    ..Negative interactions of thiols with antitumor efficacy were avoided by temporal and spatial separation of chemoprotectants and chemotherapy...
  5. ncbi request reprint Mechanisms of disease: the blood-brain barrier
    Edward A Neuwelt
    Department of Neurology, Oregon Health and Science University, Portland, Oregon 97201, USA
    Neurosurgery 54:131-40; discussion 141-2. 2004
    ..The blood-brain barrier (BBB) is often perceived as a passive membrane. However, evidence has demonstrated that the BBB plays an active role in normal homeostasis and in certain disease processes...
  6. ncbi request reprint The potential of ferumoxytol nanoparticle magnetic resonance imaging, perfusion, and angiography in central nervous system malignancy: a pilot study
    Edward A Neuwelt
    Department of Neurology, Oregon Health and Science University, Portland, OR 97239, USA
    Neurosurgery 60:601-11; discussion 611-2. 2007
    ..Our objectives were to determine the optimum time of delayed contrast enhancement of ferumoxytol, and to compare ferumoxytol and gadolinium contrast agents for magnetic resonance angiography and perfusion...
  7. ncbi request reprint Effect of antigenic heterogeneity on the efficacy of enhanced delivery of antibody-targeted chemotherapy in a human lung cancer intracerebral xenograft model in rats
    Leslie L Muldoon
    Department of Neurology, Oregon Health and Science University, and Veterans Administration Medical Center, Portland, Oregon 97201, USA
    Neurosurgery 53:1406-12; discussion 1412-3. 2003
    ..We tested whether doxorubicin released locally in antigen-expressing cells would affect adjacent non-antigen-expressing cells in heterogeneously expressing intracerebral tumors...
  8. ncbi request reprint Therapeutic efficacy of aortic administration of N-acetylcysteine as a chemoprotectant against bone marrow toxicity after intracarotid administration of alkylators, with or without glutathione depletion in a rat model
    E A Neuwelt
    Department of Neurology, Oregon Health Sciences University, Portland, Oregon 97201, USA
    Cancer Res 61:7868-74. 2001
    ....
  9. pmc Dual contrast perfusion MRI in a single imaging session for assessment of pediatric brain tumors
    Eric M Thompson
    Department of Neurological Surgery, Oregon Health and Science University, 3303 SW Bond Avenue, CH8N, Portland, OR, 97239, USA
    J Neurooncol 109:105-14. 2012
    ....
  10. pmc Magnetic resonance imaging of intracranial tumors: intra-patient comparison of gadoteridol and ferumoxytol
    Edit Dosa
    Department of Neurology, Oregon Health and Science University, 3181 S W Sam Jackson Park Road, L603, Portland, OR 97239 3098, USA
    Neuro Oncol 13:251-60. 2011
    ..Both of these functions provide useful information about tumor response to treatment. We suggest that dynamic and anatomical imaging with ferumoxytol warrant further assessment in brain tumor therapy...
  11. pmc High-resolution steady-state cerebral blood volume maps in patients with central nervous system neoplasms using ferumoxytol, a superparamagnetic iron oxide nanoparticle
    Csanad G Varallyay
    Department of Neurology, Oregon Health and Science University, Portland, Oregon, USA
    J Cereb Blood Flow Metab 33:780-6. 2013
    ..Physiologic imaging using nanoparticles will be beneficial in visualizing CNS pathologies with high vascularity that may or may not correspond with blood-brain barrier abnormalities...
  12. pmc Pseudoprogression of glioblastoma after chemo- and radiation therapy: diagnosis by using dynamic susceptibility-weighted contrast-enhanced perfusion MR imaging with ferumoxytol versus gadoteridol and correlation with survival
    Seymur Gahramanov
    Department of Neurology, Oregon Health and Science University, 3181 SW Sam Jackson Park Rd, L603, Portland, OR 97239 3098, USA
    Radiology 266:842-52. 2013
    ....
  13. pmc Blood-brain barrier disruption and intra-arterial methotrexate-based therapy for newly diagnosed primary CNS lymphoma: a multi-institutional experience
    Lilyana Angelov
    3181 SW Sam Jackson Park Rd, Mailcode L603, Portland, OR 97239, USA
    J Clin Oncol 27:3503-9. 2009
    ....
  14. pmc Efficacy and MRI of rituximab and methotrexate treatment in a nude rat model of CNS lymphoma
    Kristoph Jahnke
    Department of Neurology, Neuro Oncology, and Blood Brain Barrier Program, Oregon Health and Science University, Portland, OR, USA
    Neuro Oncol 11:503-13. 2009
    ..IV rituximab was highly effective, but methotrexate was only minimally effective. T2/FLAIR was superior to contrast-enhanced T1 for monitoring efficacy...
  15. ncbi request reprint Intraarterial chemotherapy and osmotic blood-brain barrier disruption for patients with embryonal and germ cell tumors of the central nervous system
    Kristoph Jahnke
    Department of Neurology, Oregon Health and Science University, Portland, Oregon 97239 3098, USA
    Cancer 112:581-8. 2008
    ..Intraarterial chemotherapy and osmotic blood-brain barrier disruption (IA/BBBD) increases drug delivery to the CNS...
  16. pmc Potential for differentiation of pseudoprogression from true tumor progression with dynamic susceptibility-weighted contrast-enhanced magnetic resonance imaging using ferumoxytol vs. gadoteridol: a pilot study
    Seymur Gahramanov
    Department of Neurology, Oregon Health and Science University, Portland, OR 97239 3098, USA
    Int J Radiat Oncol Biol Phys 79:514-23. 2011
    ....
  17. pmc Importance of dose intensity in neuro-oncology clinical trials: summary report of the Sixth Annual Meeting of the Blood-Brain Barrier Disruption Consortium
    N D Doolittle
    Department of Neurology, Oregon Health Sciences University, Portland 97201-3098, USA
    Neuro Oncol 3:46-54. 2001
    ..The promising role of cytoenhancers and chemoprotectants as part of dose-intensive regimens for chemosensitive brain tumors and development of improved gene therapies for malignant gliomas are discussed...
  18. ncbi request reprint An exploratory study of ferumoxtran-10 nanoparticles as a blood-brain barrier imaging agent targeting phagocytic cells in CNS inflammatory lesions
    Sándor P Manninger
    Department of Radiology, Oregon Health and Science University, Portland, OR, USA
    AJNR Am J Neuroradiol 26:2290-300. 2005
    ....
  19. pmc Imaging and therapy with rituximab anti-CD20 immunotherapy in an animal model of central nervous system lymphoma
    Leslie L Muldoon
    Department of Neurology, Oregon Health and Science University, Portland, Oregon 97239 3098, USA
    Clin Cancer Res 17:2207-15. 2011
    ....
  20. pmc Using iron oxide nanoparticles to diagnose CNS inflammatory diseases and PCNSL
    Brian T Farrell
    Department of Neurosurgery, Oregon Health and Science University, Portland, OR, USA
    Neurology 81:256-63. 2013
    ..The study goal was to assess the benefits and potential limitations in the use of ultrasmall superparamagnetic iron oxide (USPIO) nanoparticles in the MRI diagnosis of CNS inflammatory diseases and primary CNS lymphoma...
  21. pmc Long-term cognitive function, neuroimaging, and quality of life in primary CNS lymphoma
    Nancy D Doolittle
    Oregon Health and Science University, Portland, OR, USA
    Neurology 81:84-92. 2013
    ..To describe and correlate neurotoxicity indicators in long-term primary CNS lymphoma (PCNSL) survivors who were treated with high-dose methotrexate-based regimens with or without whole-brain radiotherapy (WBRT)...
  22. pmc Effect of N-acetylcysteine route of administration on chemoprotection against cisplatin-induced toxicity in rat models
    D Thomas Dickey
    Department of Neurology and Blood Brain Barrier Program, Oregon Health and Science University, 3181 SW Sam Jackson Parkway, L603, Portland, OR, 97239, USA
    Cancer Chemother Pharmacol 62:235-41. 2008
    ..Thus the protective properties of NAC are affected by the dose and route of administration...
  23. pmc Using acetaminophen's toxicity mechanism to enhance cisplatin efficacy in hepatocarcinoma and hepatoblastoma cell lines
    Alexander J Neuwelt
    Department of Neurology, Oregon Health and Science University, Portland, OR 97239, USA
    Neoplasia 11:1003-11. 2009
    ....
  24. doi request reprint Cerebrospinal fluid shunting and hearing loss in patients treated for medulloblastoma
    Daniel J Guillaume
    Department of Neurological Surgery, Oregon Health and Science University, Portland, OR 97239, USA
    J Neurosurg Pediatr 9:421-7. 2012
    ..The authors hypothesized that the incidence and severity of hearing loss in patients undergoing radiation and chemotherapy for medulloblastoma would be greater in those with shunts than in those without shunts...
  25. ncbi request reprint Potential of chemo-immunotherapy and radioimmunotherapy in relapsed primary central nervous system (CNS) lymphoma
    Nancy D Doolittle
    Department of Neurology, Oregon Health and Science University, Portland, OR 97239, USA
    Leuk Lymphoma 48:1712-20. 2007
    ....
  26. ncbi request reprint In vivo leukocyte labeling with intravenous ferumoxides/protamine sulfate complex and in vitro characterization for cellular magnetic resonance imaging
    Y Jeffrey Wu
    Research Service, Veterans Administration Medical Center, Oregon Health and Sciences University, Portland, Oregon 97239, USA
    Am J Physiol Cell Physiol 293:C1698-708. 2007
    ..These results might provide useful information for monitoring leukocyte trafficking into the brain...
  27. pmc Ultrasmall superparamagnetic iron oxides (USPIOs): a future alternative magnetic resonance (MR) contrast agent for patients at risk for nephrogenic systemic fibrosis (NSF)?
    Edward A Neuwelt
    Department of Neurology and Neurosurgery, Oregon Health and Science University, Portland, Oregon 97239, USA
    Kidney Int 75:465-74. 2009
    ..We conclude that for both CNS MR imaging and MR angiography, USPIO agents like ferumoxytol are a viable option for patients at risk for NSF...
  28. pmc Superparamagnetic iron oxide nanoparticles: diagnostic magnetic resonance imaging and potential therapeutic applications in neurooncology and central nervous system inflammatory pathologies, a review
    Jason S Weinstein
    Department of Neurological Surgery, Oregon Health and Science University, Portland, Oregon 97239, USA
    J Cereb Blood Flow Metab 30:15-35. 2010
    ....
  29. doi request reprint Correlation of MRI sequences to assess progressive glioblastoma multiforme treated with bevacizumab
    Eric M Thompson
    Department of Neurological Surgery, Oregon Health and Science University, Portland, OR 97239 3098, USA
    J Neurooncol 103:353-60. 2011
    ..63) with one exception, while correlations between T1 + GBCA and T2 were more variable (r = 0.18-0.99). These findings suggest that FLAIR MRI should be evaluated in addition to T1 + GBCA MRI when evaluating GBM responses...
  30. ncbi request reprint Comparison of two superparamagnetic viral-sized iron oxide particles ferumoxides and ferumoxtran-10 with a gadolinium chelate in imaging intracranial tumors
    Peter Varallyay
    Department of Neurology, Oregon Health and Science University, Portland, Oregon 97201, USA
    AJNR Am J Neuroradiol 23:510-9. 2002
    ....
  31. pmc Comparative analysis of ferumoxytol and gadoteridol enhancement using T1- and T2-weighted MRI in neuroimaging
    Bronwyn E Hamilton
    Department of Radiology, Oregon Health and Science University, 3181 SW Sam Jackson Park Rd, Mail Code CR 135, Portland, OR 97239, USA
    AJR Am J Roentgenol 197:981-8. 2011
    ..We compared ferumoxytol to gadoteridol enhancement on T1- and T2-weighted MRI in CNS disorders to explore its diagnostic utility...
  32. pmc Acetaminophen enhances cisplatin- and paclitaxel-mediated cytotoxicity to SKOV3 human ovarian carcinoma
    Ying Jen Jeffrey Wu
    Department of Neurology, Oregon Health and Sciences University, Portland, OR 97239, USA
    Anticancer Res 33:2391-400. 2013
    ..Acetaminophen reduced glutathione and enhanced chemotherapy efficacy in hepatic cancer treatment. The objective of this study was to examine if acetaminophen enhances the cytotoxicity of cisplatin/paclitaxel in ovarian cancer...
  33. ncbi request reprint Delivery of chemotherapy and antibodies across the blood-brain barrier and the role of chemoprotection, in primary and metastatic brain tumors: report of the Eleventh Annual Blood-Brain Barrier Consortium meeting
    Nancy D Doolittle
    Department of Neurology, Oregon Health and Science University, 3181 S W Sam Jackson Park Road L603, Portland, OR 97239 3098, USA
    J Neurooncol 81:81-91. 2007
    ....
  34. pmc Improved perfusion MR imaging assessment of intracerebral tumor blood volume and antiangiogenic therapy efficacy in a rat model with ferumoxytol
    Seymur Gahramanov
    Department of Neurology and Neurosurgery, Oregon Health and Science University, 3181 SW Sam Jackson Park Rd, Room L603, Portland, OR 97239 3098, USA
    Radiology 261:796-804. 2011
    ....
  35. ncbi request reprint BR96-DOX immunoconjugate targeting of chemotherapy in brain tumor models
    Leslie L Muldoon
    Department of Neurology, Oregon Health and Sciences University, Portland, OR 97201, USA
    J Neurooncol 65:49-62. 2003
    ..We review additional studies of drug-mAb immunoconjugates pertinent to the treatment of gliomas...
  36. ncbi request reprint Chemotherapy delivery issues in central nervous system malignancy: a reality check
    Leslie L Muldoon
    Department of Neurology, Oregon Health and Science University, Portland, and the Veterans Administration Medical Center, OR 97239 3098, USA
    J Clin Oncol 25:2295-305. 2007
    ..This review assesses the current state of knowledge regarding preclinical and clinical pharmacology for brain tumor chemotherapy and evaluates relevant brain tumor pharmacology studies before October 2006...
  37. ncbi request reprint New frontiers in translational research in neuro-oncology and the blood-brain barrier: report of the tenth annual Blood-Brain Barrier Disruption Consortium Meeting
    Nancy D Doolittle
    Department of Neurology, Oregon Health and Science University, 3181 SW Sam Jackson Park Road, Portland, OR 97201, USA
    Clin Cancer Res 11:421-8. 2005
    ..Transport across the BBB relates to the neurovascular unit, which consists not only of endothelial cells but also of pericyte, glia, and neuronal elements...
  38. pmc Targeting αV-integrins decreased metastasis and increased survival in a nude rat breast cancer brain metastasis model
    Y Jeffrey Wu
    Department of Neurology, Oregon Health and Sciences University, Portland, OR 97239, USA
    J Neurooncol 110:27-36. 2012
    ..The overall survival was improved by intetumumab compared to controls (median 77+ vs. 52 days, p = 0.0277). Our results suggest that breast cancer patients at risk of metastases might benefit from early intetumumab treatment...
  39. pmc The effect of alpha-v integrin inhibition on the malignant characteristics of medulloblastoma
    Eric M Thompson
    Department of Neurological Surgery, Oregon Health and Science University, Portland, OR, USA
    J Neurosurg Pediatr 11:60-7. 2013
    ....
  40. ncbi request reprint Characterization and magnetic resonance imaging of a rat model of human B-cell central nervous system lymphoma
    Carole Soussain
    Department of Neurology, Oregon Health and Science University, Portland, Oregon 97239 3098, USA
    Clin Cancer Res 13:2504-11. 2007
    ..The incidence of primary central nervous system lymphoma (PCNSL) is increasing. Therapeutic approaches remain controversial. An animal model that mimics the clinical situation would be useful for evaluating PCNSL biology and treatment...
  41. ncbi request reprint Toxicity profile of delayed high dose sodium thiosulfate in children treated with carboplatin in conjunction with blood-brain-barrier disruption
    Edward A Neuwelt
    Department of Neurology, Oregon Health and Science University Portland, Portland, Oregon 97239, USA
    Pediatr Blood Cancer 47:174-82. 2006
    ..v.) sodium thiosulfate (STS) in a case series of 12 children with malignant brain tumors who were treated with intraarterial (i.a.) carboplatin in conjunction with blood-brain-barrier disruption (BBBD)...
  42. pmc Cyclophosphamide enhances human tumor growth in nude rat xenografted tumor models
    Yingjen Jeffrey Wu
    Department of Neurology, Oregon Health and Sciences University, Portland, OR 97239, USA
    Neoplasia 11:187-95. 2009
    ..These findings may be clinically relevant because chemotherapy may predispose human cancer subjects to tumor growth in the brain or other tissues...
  43. pmc Intra-arterial chemotherapy with osmotic blood-brain barrier disruption for aggressive oligodendroglial tumors: results of a phase I study
    Daniel J Guillaume
    Department of Neurosurgery, Oregon Health and Science University, Portland, Oregon, USA
    Neurosurgery 66:48-58; discussion 58. 2010
    ..The secondary measure was efficacy...
  44. pmc Dynamic-contrast-enhanced-MRI with extravasating contrast reagent: rat cerebral glioma blood volume determination
    Xin Li
    W M Keck Foundation High Field MRI Laboratory Advanced Imaging Research Center, Oregon Health and Science University, Portland, OR 97239, United States
    J Magn Reson 206:190-9. 2010
    ..Tumor blood volume (vb), as well as ve (the extracellular, extravascular space volume fraction), and Ktrans (a CR extravasation rate measure) parametric maps are presented. The role of the Patlak Plot in DCE-MRI is also considered...
  45. ncbi request reprint Brain parenchyma involvement as isolated central nervous system relapse of systemic non-Hodgkin lymphoma: an International Primary CNS Lymphoma Collaborative Group report
    Nancy D Doolittle
    Department of Neurology, Oregon Health and Science University, Portland, OR 97239, USA
    Blood 111:1085-93. 2008
    ..Our results suggest systemic methotrexate is the optimal treatment for isolated CNS relapse involving the brain parenchyma. Long-term survival is possible in some patients...
  46. ncbi request reprint Protection against cisplatin-induced toxicities by N-acetylcysteine and sodium thiosulfate as assessed at the molecular, cellular, and in vivo levels
    D Thomas Dickey
    Oregon Health and Science University, Department of Neurology, Portland, 97239, USA
    J Pharmacol Exp Ther 314:1052-8. 2005
    ..Thus, the chemoprotection route and timing of administration can be manipulated to maintain CDDP antitumor efficacy while protecting against toxicities...
  47. pmc Dynamic magnetic resonance imaging assessment of vascular targeting agent effects in rat intracerebral tumor models
    Leslie L Muldoon
    Department of Neurology, Oregon Health and Science University, 3181 S W Sam Jackson Park Road, L603, Portland, OR 97239 3098, USA
    Neuro Oncol 13:51-60. 2011
    ..Targeting α(V)-integrins increased tumor vascular permeability and blood volume, whereas bevacizumab decreased both measures. These findings have implications for chemotherapy delivery and antitumor efficacy...
  48. ncbi request reprint Delayed sodium thiosulfate as an otoprotectant against carboplatin-induced hearing loss in patients with malignant brain tumors
    N D Doolittle
    Department of Neurology, Oregon Health Sciences University, Portland 97201, USA
    Clin Cancer Res 7:493-500. 2001
    ..0018). Delayed STS was effective in protecting against carboplatin-induced hearing loss. STS delayed to 4 h after carboplatin significantly decreased time to development of ototoxicity and rate of ototoxicity when compared with HCG...
  49. ncbi request reprint Efficacy after sequencing of brain radiotherapy and enhanced antibody targeted chemotherapy delivery in a rodent human lung cancer brain xenograft model
    L G Remsen
    Department of Neurology, Oregon Health Sciences University, Portland, OR, USA
    Int J Radiat Oncol Biol Phys 51:1045-9. 2001
    ..Moreover, BR96-DOX administration prior to RT significantly increased survival compared to those receiving RT and chemotherapy concurrently (p < 0.05)...
  50. ncbi request reprint Association of total dose intensity of chemotherapy in primary central nervous system lymphoma (human non-acquired immunodeficiency syndrome) and survival
    D F Kraemer
    Division of Medical Informatics and Outcomes Research, Oregon Health Sciences University, Portland 97201-3098, USA
    Neurosurgery 48:1033-40; discussion 1040-1. 2001
    ..These results probably constitute the strongest evidence to date of the importance of total dose intensity in treating CNS malignancies...
  51. ncbi request reprint Rescue from enhanced alkylator-induced cell death with low molecular weight sulfur-containing chemoprotectants
    L L Muldoon
    Department of Neurology, Oregon Health Sciences University, Portland, Oregon 97201, USA
    J Pharmacol Exp Ther 296:797-805. 2001
    ....
  52. ncbi request reprint Targeted delivery in primary and metastatic brain tumors: summary report of the seventh annual meeting of the Blood-Brain Barrier Disruption Consortium
    Nancy D Doolittle
    Department of Neurology, Oregon Health and Science University, 3181 SW Sam Jackson Park Road L603, Portland, OR 97201 3098, USA
    Clin Cancer Res 8:1702-9. 2002
    ....
  53. ncbi request reprint Single-dose contrast agent for intraoperative MR imaging of intrinsic brain tumors by using ferumoxtran-10
    Matthew A Hunt
    Department of Neurosurgery, Oregon Health and Science University, Portland, OR 97239, USA
    AJNR Am J Neuroradiol 26:1084-8. 2005
    ..These trapped particles provide a method to demonstrate enhancing lesions without the artifact of repeat gadolinium administration in the face of blood brain barrier and vascular injury...
  54. doi request reprint N-acetylcysteine use to prevent contrast medium-induced nephropathy: premature phase III trials
    David A Stenstrom
    Department of Neurology, Oregon Health and Science University, Portland, Oregon 97239, USA
    J Vasc Interv Radiol 19:309-18. 2008
    ..The efficacy of N-acetylcysteine in the prevention of contrast medium-induced nephropathy may be demonstrated with the use of higher doses than used in earlier studies, in combination with parenteral administration...
  55. ncbi request reprint Trafficking of superparamagnetic iron oxide particles (Combidex) from brain to lymph nodes in the rat
    L L Muldoon
    Department of Neurology, Division of Medical Informatics and Outcomes Research, Oregon Health and Science University, OR 97239, USA
    Neuropathol Appl Neurobiol 30:70-9. 2004
    ..0003). The trafficking of the superparamagnetic iron particles from the CNS in the rat could be visualized by MRI and histology. Combidex provides a powerful tool to rapidly assess drainage of virus-sized particles from the CNS...
  56. ncbi request reprint Severe ocular and orbital toxicity after intracarotid etoposide phosphate and carboplatin therapy
    A K Lauer
    Department of Ophthalmology, Casey Eye Institute, Oregon Health Sciences University, Portland 97201 4197, USA
    Am J Ophthalmol 127:230-3. 1999
    ..To report severe ocular and orbital toxicity after administration of intracarotid etoposide phosphate and carboplatin...
  57. pmc Inhibition of SUR1 decreases the vascular permeability of cerebral metastases
    Eric M Thompson
    Department of Neurological Surgery, Oregon Health and Science University, Portland, OR 97239, USA
    Neoplasia 15:535-43. 2013
    ..Glyburide is a safe, inexpensive, and efficacious alternative to dexamethasone for the treatment of cerebral metastasis-related vasogenic edema...
  58. doi request reprint Treatment with bevacizumab plus carboplatin for recurrent malignant glioma
    Eric M Thompson
    Department of Neurological Surgery, Oregon Health and Science University, Portland, Oregon 97239, USA
    Neurosurgery 67:87-93. 2010
    ..The secondary objective was to estimate the agreement between postcontrast T1-weighted and T2-weighted magnetic resonance imaging...
  59. pmc The paradoxical effect of bevacizumab in the therapy of malignant gliomas
    Eric M Thompson
    Department of Neurological Surgery, Blood Brain Barrier Program, Oregon Health and Science University, 3181 Sam Jackson Parkway Road, L603, Portland, OR 97239, USA
    Neurology 76:87-93. 2011
    ....
  60. ncbi request reprint Early changes in auditory function as a result of platinum chemotherapy: use of extended high-frequency audiometry and evoked distortion product otoacoustic emissions
    Kristin R Knight
    Department of Pediatric Audiology, Child Development and Rehabilitation Center, Portland, Oregon, USA
    J Clin Oncol 25:1190-5. 2007
    ....
  61. ncbi request reprint Protection against cisplatin-induced ototoxicity by N-acetylcysteine in a rat model
    D Thomas Dickey
    Department of Neurology, Oregon Health and Science University, Portland, OR 97201 3098, USA
    Hear Res 193:25-30. 2004
    ..63 g; mean for NAC=-21.13 g; p=0.0084). These data show that treatment with NAC can prevent CDDP-induced ototoxicity in rats...
  62. ncbi request reprint Herstatin, an autoinhibitor of the epidermal growth factor receptor family, blocks the intracranial growth of glioblastoma
    Julia A Staverosky
    Department of Biochemistry and Molecular Biology, Oregon Health and Science University, Portland, Oregon 97239, USA
    Clin Cancer Res 11:335-40. 2005
    ..Herstatin, an autoinhibitor of the epidermal growth factor (EGF) receptor family, was evaluated for efficacy against human glioblastoma in vitro and in vivo in a rat intracranial model...
  63. ncbi request reprint Report of an international workshop to standardize baseline evaluation and response criteria for primary CNS lymphoma
    Lauren E Abrey
    Department of Neurology, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    J Clin Oncol 23:5034-43. 2005
    ..We hope that these guidelines will improve communication among investigators and comparability among clinical trials in a way that will allow us to develop better therapies for patients...
  64. ncbi request reprint The chemoprotective agent N-acetylcysteine blocks cisplatin-induced apoptosis through caspase signaling pathway
    Y Jeffrey Wu
    Department of Neurology, Oregon Health and Sciences University, 3181 Sam Jackson Parkway, L603, Portland, OR 97239, USA
    J Pharmacol Exp Ther 312:424-31. 2005
    ....
  65. pmc MRI using ferumoxytol improves the visualization of central nervous system vascular malformations
    Edit Dosa
    Department of Neurology, Oregon Health and Science University, 3181 SW Sam Jackson Park Road, L603, Portland, OR 97239 3098, USA
    Stroke 42:1581-8. 2011
    ....
  66. ncbi request reprint Imaging, distribution, and toxicity of superparamagnetic iron oxide magnetic resonance nanoparticles in the rat brain and intracerebral tumor
    Leslie L Muldoon
    Department of Neurology, Oregon Health and Sciences University, Portland, Oregon, USA
    Neurosurgery 57:785-96; discussion 785-96. 2005
    ..The purpose of this study was to evaluate the imaging characteristics, distribution, time course, and neurotoxicity of the clinical agents ferumoxtran-10, ferumoxides, and ferumoxytol, and the laboratory preparation MION-46 in rat brain...
  67. ncbi request reprint Combined intraarterial carboplatin, intraarterial etoposide phosphate, and IV Cytoxan chemotherapy for progressive optic-hypothalamic gliomas in young children
    E Osztie
    Department of Neurology, Oregon Health Sciences University, 3181 SW Sam Jackson Park Road, Portland, OR 92701, USA
    AJNR Am J Neuroradiol 22:818-23. 2001
    ....
  68. ncbi request reprint Implications of the blood-brain barrier in primary central nervous system lymphoma
    Kristoph Jahnke
    Department of Neurology, Oregon Health and Science University, Portland, Oregon, USA
    Neurosurg Focus 21:E11. 2006
    ..Regarding the evaluation of more sensitive and specific diagnostic imaging tools, iron oxide-based contrast agents for magnetic resonance imaging have shown promise for better differentiation of PCNSL from other white matter diseases...
  69. ncbi request reprint Distinguishing primary central nervous system lymphoma from other central nervous system diseases: a neurosurgical perspective on diagnostic dilemmas and approaches
    Matthew A Hunt
    Department of Neurosurgery, Oregon Health and Science University, 3181 SW Sam Jackson Park Road, L603 Portland, Oregon 97239 3098, USA
    Neurosurg Focus 21:E3. 2006
    ..Unfortunately, delayed diagnosis and treatment of PCNSL can negatively affect prognosis...
  70. ncbi request reprint Ototoxicity in children receiving platinum chemotherapy: underestimating a commonly occurring toxicity that may influence academic and social development
    Kristin R Gilmer Knight
    Department of Neurology, Neurosurgery, and Pediatric Audiology, Oregon Health and Science University, Portland 97201, USA
    J Clin Oncol 23:8588-96. 2005
    ..To describe the frequency and severity of ototoxicity in a series of pediatric patients treated with platinum-based chemotherapy...
  71. ncbi request reprint Chemotherapeutic dose intensification for treatment of malignant brain tumors: recent developments and future directions
    Dale F Kraemer
    Department of Neurology, Oregon Health and Science University, 3181 S W Sam Jackson Park Road, Portland, OR 97201, USA
    Curr Neurol Neurosci Rep 2:216-24. 2002
    ..We also discuss approaches to improve the design of nonrandomized trials by identifying and controlling potential confounding variables. This will improve the quality of individual studies and perhaps the comparability across studies...
  72. ncbi request reprint Role of intravitreal methotrexate in the management of primary central nervous system lymphoma with ocular involvement
    Justine R Smith
    Casey Eye Institute, Oregon Health and Science University, Portland, Oregon 97201 4197, USA
    Ophthalmology 109:1709-16. 2002
    ..To evaluate the safety and efficacy of intravitreal methotrexate in the management of primary central nervous system lymphoma (PCNSL) involving the eye...
  73. ncbi request reprint Advances in the understanding of the blood-brain barrier in neuro-oncology
    Robert M Quencer
    Oregon Health and Science University, USA
    AJNR Am J Neuroradiol 23:1807-10. 2002
  74. ncbi request reprint Imaging and nanomedicine for diagnosis and therapy in the central nervous system: report of the eleventh annual Blood-Brain Barrier Disruption Consortium meeting
    L L Muldoon
    Department of Neurology, Oregon Health and Science University, Portland, Ore 97239 3098, USA
    AJNR Am J Neuroradiol 27:715-21. 2006
    ..Discussions at this meeting stressed the role of biotechnology in the convergence of CNS imaging and nanomedicine and are summarized in this article...
  75. pmc Immunologic privilege in the central nervous system and the blood-brain barrier
    Leslie L Muldoon
    Department of Neurology, Oregon Health and Science University, Portland, OR, USA
    J Cereb Blood Flow Metab 33:13-21. 2013
    ..This review article was developed from reports presented at the 2011 Annual Blood-Brain Barrier Consortium Meeting...
  76. ncbi request reprint Can medical schools teach high school students to be scientists?
    James T Rosenbaum
    Oregon Health and Science University, 3181 SW Sam Jackson Park Rd L467Ad, Portland, OR 97239, USA
    FASEB J 21:1954-7. 2007
    ..A federal initiative could facilitate student opportunities to pursue research...
  77. doi request reprint Temozolomide for corticotroph pituitary adenomas refractory to standard therapy
    Troy H Dillard
    Division of Endocrinology, Diabetes, and Clinical Nutrition, Department of Medicine, Oregon Health and Science University, Portland, OR 97239, USA
    Pituitary 14:80-91. 2011
    ..To our knowledge, this case represents the most rapid robust CA shrinkage response reported to date. Further randomized clinical trials of TMZ in the treatment of aggressive pituitary adenomas are warranted...
  78. pmc Characterization of the molecular defect in a feline model for type II GM2-gangliosidosis (Sandhoff disease)
    L L Muldoon
    Department of Neurology, Oregon Health Sciences University, Portland 97201
    Am J Pathol 144:1109-18. 1994
    ..In addition, alternative splicing of both normal and affected messenger RNAs was demonstrated. These results should facilitate the use of this animal model to assess gene therapy...
  79. pmc Engaging neuroscience to advance translational research in brain barrier biology
    Edward A Neuwelt
    Oregon Health and Science University, 3181 SW Sam Jackson Park Road L603, Portland, Oregon 97239 2941, USA
    Nat Rev Neurosci 12:169-82. 2011
    ....
  80. doi request reprint Late occurrence of drop metastasis to the spine in a case of esthesioneuroblastoma
    Abigail J Rao
    Department of Neurological Surgery, Oregon Health and Science University, Portland, Oregon 97239, USA
    J Neurosurg Spine 15:571-5. 2011
    ..The symptomatic lesion was treated with resection and adjuvant chemotherapy. The options available for treatment of this disease are summarized with a review of the few reported cases of spinal metastasis of esthesioneuroblastoma...
  81. doi request reprint Primary CNS lymphoma with intraocular involvement: International PCNSL Collaborative Group Report
    S A Grimm
    Department of Neurology, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Neurology 71:1355-60. 2008
    ..To describe the demographics, diagnostic details, therapeutic management, and outcome in patients with primary CNS lymphoma (PCNSL) with ocular involvement...

Research Grants66

  1. TWO COMPARTMENT MODELS TO IMPROVE BRAIN TUMOR THERAPY
    Edward A Neuwelt; Fiscal Year: 2010
    ..Perform clinical trials of antibody-based therapy and neurotoxicity in human primary central nervous system lymphoma. ..
  2. CNS Gene Delivery and Imaging in Brain Tumor Therapy
    Edward Neuwelt; Fiscal Year: 2006
    ..abstract_text> ..
  3. TWO COMPARTMENT MODELS TO IMPROVE BRAIN TUMOR THERAPY
    Edward Neuwelt; Fiscal Year: 2004
    ..This proposal is response to Brain Tumor PRG sponsored by NINDS and NCI. ..
  4. CNS Gene Delivery and Imaging in Brain Tumor Therapy
    Edward Neuwelt; Fiscal Year: 2004
    ..abstract_text> ..
  5. TWO COMPARTMENT MODELS TO IMPROVE BRAIN TUMOR THERAPY
    Edward Neuwelt; Fiscal Year: 2005
    ..This proposal is response to Brain Tumor PRG sponsored by NINDS and NCI. ..
  6. CNS Gene Delivery and Imaging in Brain Tumor Therapy
    Edward Neuwelt; Fiscal Year: 2005
    ..abstract_text> ..
  7. TWO COMPARTMENT MODELS TO IMPROVE BRAIN TUMOR THERAPY
    Edward Neuwelt; Fiscal Year: 2004
    ..This proposal is response to Brain Tumor PRG sponsored by NINDS and NCI. ..
  8. CNS Gene Delivery and Imaging in Brain Tumor Therapy
    Edward Neuwelt; Fiscal Year: 2004
    ..abstract_text> ..
  9. CNS Gene Delivery and Imaging in Brain Tumor Therapy
    Edward Neuwelt; Fiscal Year: 2003
    ..abstract_text> ..
  10. TWO COMPARTMENT MODELS TO IMPROVE BRAIN TUMOR THERAPY
    Edward Neuwelt; Fiscal Year: 2003
    ..This proposal is response to Brain Tumor PRG sponsored by NINDS and NCI. ..
  11. TWO COMPARTMENT MODELS TO IMPROVE BRAIN TUMOR THERAPY
    Edward Neuwelt; Fiscal Year: 2002
    ..The proposed studies will further enhance these positive clinical results. ..
  12. CNS GENE DELIVERY AND EFFICACY IN BRAIN TUMOR THERAPY
    Edward Neuwelt; Fiscal Year: 2001
    ..We anticipate that these studies will provide the basis for a clinical trial of osmotic BBB opening for brain tumor gene therapy. ..
  13. TWO COMPARTMENT MODELS TO IMPROVE BRAIN TUMOR THERAPY
    Edward Neuwelt; Fiscal Year: 2001
    ..The proposed studies will further enhance these positive clinical results. ..
  14. TWO COMPARTMENT MODELS TO IMPROVE BRAIN TUMOR THERAPY
    Edward Neuwelt; Fiscal Year: 2000
    ..The proposed studies will further enhance these positive clinical results. ..
  15. OPENING OF THE BLOOD-BRAIN BARRIER TO ANTITUMOR AGENTS
    Edward Neuwelt; Fiscal Year: 2001
    ..This revised competitive renewal is the continuation of a surgical CREG. ..
  16. TWO COMPARTMENT MODELS TO IMPROVE BRAIN TUMOR THERAPY
    Edward Neuwelt; Fiscal Year: 2005
    ..This proposal is response to Brain Tumor PRG sponsored by NINDS and NCI. ..
  17. TWO COMPARTMENT MODELS TO IMPROVE BRAIN TUMOR THERAPY
    Edward Neuwelt; Fiscal Year: 2006
    ..This proposal is response to Brain Tumor PRG sponsored by NINDS and NCI. ..
  18. TWO COMPARTMENT MODELS TO IMPROVE BRAIN TUMOR THERAPY
    Edward Neuwelt; Fiscal Year: 2009
    ..Perform clinical trials of antibody-based therapy and neurotoxicity in human primary central nervous system lymphoma. ..
  19. OPENING OF THE BLOOD-BRAIN BARRIER TO ANTITUMOR AGENTS
    Edward A Neuwelt; Fiscal Year: 2010
    ..Aims 1-3 are preclinical studies of modulating glutathione, and aim 4 will be clinical trials of thiol chemoprotection with the goal of testing chemo-enhancement in brain tumor subjects. ..
  20. Nanoparticle MR Imaging of BBB Inflammation at High Tesla in CNS Tumors
    Edward A Neuwelt; Fiscal Year: 2010
    ..This proposal is responsive to PAS-03-165. ..
  21. TWO COMPARTMENT MODELS TO IMPROVE BRAIN TUMOR THERAPY
    Edward Neuwelt; Fiscal Year: 2009
    ..Perform clinical trials of antibody-based therapy and neurotoxicity in human primary central nervous system lymphoma. ..
  22. Nanoparticle MR Imaging of BBB Inflammation at High Tesla in CNS Tumors
    Edward Neuwelt; Fiscal Year: 2009
    ..This proposal is responsive to PAS-03-165. ..
  23. TWO COMPARTMENT MODELS TO IMPROVE BRAIN TUMOR THERAPY
    Edward Neuwelt; Fiscal Year: 2007
    ..This proposal is response to Brain Tumor PRG sponsored by NINDS and NCI. ..
  24. Opening of the Blood Brain Barrier to Antitumor Agents
    Edward Neuwelt; Fiscal Year: 2007
    ..This revised competitive renewal is the continuation of the original 1978 surgical CREG, and is responsive to the priorities established in July 2000 by the joint NINDS and NCI Brain Tumor PRG. ..
  25. CNS Gene Delivery and Imaging in Brain Tumor Therapy
    Edward Neuwelt; Fiscal Year: 2007
    ..abstract_text> ..
  26. Nanoparticle MR Imaging of BBB Inflammation at High Tesla in CNS Tumors
    Edward Neuwelt; Fiscal Year: 2007
    ..This proposal is responsive to PAS-03-165. ..
  27. The Annual Blood-Brain Barrier Consortium Meeting
    Edward Neuwelt; Fiscal Year: 2007
    ..abstract_text> ..
  28. TWO COMPARTMENT MODELS TO IMPROVE BRAIN TUMOR THERAPY
    Edward Neuwelt; Fiscal Year: 2000
    ..The proposed studies will further enhance these positive clinical results. ..
  29. CNS GENE DELIVERY AND EFFICACY IN BRAIN TUMOR THERAPY
    Edward Neuwelt; Fiscal Year: 2000
    ..We anticipate that these studies will provide the basis for a clinical trial of osmotic BBB opening for brain tumor gene therapy. ..
  30. TWO COMPARTMENT MODELS TO IMPROVE BRAIN TUMOR THERAPY
    Edward Neuwelt; Fiscal Year: 1999
    ..The proposed studies will further enhance these positive clinical results. ..
  31. OPENING THE BLOOD-BRAIN BARRIER TO ANTITUMOR AGENTS
    Edward Neuwelt; Fiscal Year: 1993
    ..This proposal is in response to the program announcement in surgical oncology and is a continuation of a surgical CREG...
  32. CNS GENE DELIVERY AND EFFICACY IN BRAIN TUMOR THERAPY
    Edward Neuwelt; Fiscal Year: 1999
    ..We anticipate that these studies will provide the basis for a clinical trial of osmotic BBB opening for brain tumor gene therapy. ..
  33. OPENING OF THE BLOOD-BRAIN BARRIER TO ANTITUMOR AGENTS
    Edward Neuwelt; Fiscal Year: 1999
    ..This revised competitive renewal is the continuation of a surgical CREG. ..
  34. CNS GENE DELIVERY AND EFFICACY IN BRAIN TUMOR THERAPY
    Edward Neuwelt; Fiscal Year: 1999
    ..Tumor killing and vector toxicity will be assessed by comparing tumor size, virus distribution, gene expression and animal survival. In aim 4, the vector system will be tested for toxicity in primates. ..
  35. OSMOTIC OPENING OF THE BLOOD-BRAIN BARRIER
    Edward Neuwelt; Fiscal Year: 1991
    ..Our overall objective is to improve delivery to antitumor agents to the brain & brain tumors. This proposal is in response to the program announcement in Surgical Oncology & is a continuation of a surgical CREG...
  36. OSMOTIC OPENING OF THE BLOOD-BRAIN BARRIER
    Edward Neuwelt; Fiscal Year: 1990
    ..Our overall objective is to improve delivery to antitumor agents to the brain & brain tumors. This proposal is in response to the program announcement in Surgical Oncology & is a continuation of a surgical CREG...
  37. OPENING OF THE BLOOD-BRAIN BARRIER TO ANTITUMOR AGENTS
    Edward Neuwelt; Fiscal Year: 2000
    ..This revised competitive renewal is the continuation of a surgical CREG. ..
  38. OSMOTIC OPENING OF THE BLOOD-BRAIN BARRIER
    Edward Neuwelt; Fiscal Year: 1992
    ..Our overall objective is to improve delivery to antitumor agents to the brain & brain tumors. This proposal is in response to the program announcement in Surgical Oncology & is a continuation of a surgical CREG...